Herbs that might be effective for the management of COVID-19: A bioinformatics analysis on anti-tyrosine kinase property

COVID-19 is an important new infectious disease that affects >150 countries worldwide. This respiratory infection is a public health emergency to be managed. As a new disease, there is limited knowledge of treatment. In general, many drugs are tests for possible efficacy in disease management. The widely used antiviral drugs include oseltamivir and anti-HIV drugs.^[1] In medical science, there are also attempts to find herbs, natural products, which might be effective in the treatment of the coronavirus disease.^[2] In the previous report, an important target that is useful for the treatment of coronavirus disease is tyrosine kinase.^[3] Any herbs that pose

anti-tyrosine kinase property might be useful for the treatment of COVID-19. Here, the authors perform a pharmacoinformatics study to search for herbs that have antipeptidase property and might be useful. Using the same database mining technique as in the referencing publication,[4] the PubMed database is used as a primary tool for data mining. According to data mining, there are at least herbs that present anti-tyrosine kinase properties and might be useful for the treatment of COVID-19. Those herbs are Hesperethusa crenulata, [5] Perilla frutescens, [6] Ephedra equisetina,[7] Shiraia bambusicola,[8] Panax ginseng[9] and Carthamus tinctorius L [Table 1].[10] Of interest, those herbs are the classical well-known herbs in East Asia, where the COVID-19 first emerged. The present data mining is only to roughly include potential herbs for further studies on the possible usefulness in the management of COVID-19. Some of these herbs are already confirmed for their advantages in the management of viral respiratory infections. For example, E. equisetina and P. ginseng are confirmed for its anti-influenza property.[11,12]

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

Herbs	Origin	Ehnopharmacological indication	Administration	Dose/day*
Hesperethusa crenulata Perilla frutescens Ephedra equisetina Shiraia bambusicola Panax ginseng Carthamus tinctorius L.	Myanmar	Dermatological disorder	Skin paste	Powder paste
	Myanmar, China	Gastrointestinal disorder	Ingestion	2.5 g
	Japan	Cardiovascular disorder	Ingestion	30 mg
	China	Respiratory disorder	Ingestion	25 mg
	Korea, China	Many disorder30	Ingestion	6 g
	Korea	Cardiovascular disorder	Ingestion	30 g

^{*}Dose is referred to local ethnopharmacological practice

1

Won Sriwijitalai1, Viroj Wiwanitkit2,3,4

¹Private Academic Writer/Consultant, Bangkok, Thailand, ²Department of Community Medicine, Dr. DY Patil University, Pune, Maharashtra, India, ³Department of Tropical Medicine, Hainan Medical University, Haikou, China, ⁴Department of Biological Science, Joseph Ayobabalola University, Ikeji-Arakeji, Nigeria

Address for correspondence: Dr. Won Sriwijitalai, RVT Medical Center, Bangkok, Thailand. E-mail: wonsriwi@gmail.com

Submitted: 28-Mar-2020; Revised: 04-Apr-2020; Accepted: 15-Apr-2020; Published: 06-May-2020

REFERENCES

- Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 2020;14:58-60.
- Ling CQ. Traditional Chinese medicine is a resource for drug discovery against 2019 novel coronavirus (SARS-CoV-2). J Integr Med 2020;18:87-8.
- Sisk JM, Frieman MB, Machamer CE. Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors. J Gen Virol 2018;99:619-30.
- Wiwanitkit V. Analysis of Mycobacterium leprae genome: In silico searching for drug targets. Southeast Asian J Trop Med Public Health 2005;36 Suppl 4:225-7.
- Wangthong S, Palaga T, Rengpipat S, Wanichwecharungruang SP, Chanchaisak P, Heinrich M. Biological activities and safety of Thanaka (*Hesperethusa crenulata*) stem bark. J Ethnopharmacol 2010;132:466-72.
- El-Hafeez AA, Fujimura T, Kamei R, Hirakawa N, Baba K, Ono K, et al. Synergistic tumor suppression by a Perilla frutescens-derived methoxyflavanone and anti-cancer tyrosine kinase inhibitors in A549 human lung adenocarcinoma. Cytotechnology 2018;70:913-9.
- Hyuga S. The pharmacological actions of ephedrine alkaloids-free ephreda herb extract and preparation for clinical application. Yakugaku Zasshi 2017;137:179-86.
- Zhang YX, Chen Y, Guo XN, Zhang XW, Zhao WM, Zhong L, et al. 11,11'-dideoxy-verticillin: A natural compound possessing growth factor receptor tyrosine kinase-inhibitory effect with anti-tumor

- activity. Anticancer Drugs 2005;16:515-24.
- Sathishkumar N, Karpagam V, Sathiyamoorthy S, Woo MJ, Kim YJ, Yang DC. Computer-aided identification of EGFR tyrosine kinase inhibitors using ginsenosides from Panax ginseng. Comput Biol Med 2013;43:786-97.
- Yuk TH, Kang JH, Lee SR, Yuk SW, Lee KG, Song BY, et al. Inhibitory effect of Carthamus tinctorius L. seed extracts on bone resorption mediated by tyrosine kinase, COX-2 (cyclooxygenase) and PG (prostaglandin) E2. Am J Chin Med 2002;30:95-108.
- Hyuga S, Hyuga M, Oshima N, Maruyama T, Kamakura H, Yamashita T, et al. Ephedrine alkaloids-free ephedra herb extract: A safer alternative to ephedra with comparable analgesic, anticancer, and anti-influenza activities. J Nat Med 2016;70:571-83.
- 12. Scaglione F, Cattaneo G, Alessandria M, Cogo R. Efficacy and safety of the standardised Ginseng extract G115 for potentiating vaccination against the influenza syndrome and protection against the common cold [corrected]. Drugs Exp Clin Res 1996;22:65-72.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Access this article online Quick Response Code: Website: www.jmsjournal.net DOI: 10.4103/jrms.JRMS_312_20

How to cite this article: Sriwijitalai W, Wiwanitkit V. Herbs that might be effective for the management of COVID-19: A bioinformatics analysis on anti-tyrosine kinase property. J Res Med Sci 2020;25:44.

 $@\,2020\,Journal\,of\,Research\,in\,Medical\,Sciences\,|\,Published\,by\,Wolters\,Kluwer\,-\,Medknow$